Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer
Pedro C. BarataTulane University, New Orleans, LA, USAMatthew M. CooneySeidman Cancer Center, Case Comprehensive Cancer Center, University Hospitals, Cleveland, OH, USAPrateek MendirattaSeidman Cancer Center, Case Comprehensive Cancer Center, University Hospitals, Cleveland, OH, USARuby GuptaCleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave/CA60, Cleveland, OH, 44195, USARobert DreicerDivision of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA, USAJorge A. GarcíaCleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave/CA60, Cleveland, OH, 44195, USA. [email protected]
2018en
ABI
Аннотация
Аннотация мавжуд эмас.
Идентификаторлар
Иқтибослар ва манбалар
2 та иқтибос0 та фойдаланилган манба